Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. ETF
  3. OTLK
OTLK logo

OTLK

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewTechnicalNews
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

OTLK News

Outlook Therapeutics Shares Drop 34% After Pricing Public Offering

6d agoseekingalpha

Outlook Therapeutics Plans Public Offering Amid Stock Plunge

6d agostocktwits

U.S. Stock Futures Cautious, NETGEAR Shares Surge

Mar 24 2026seekingalpha

Outlook Therapeutics Proposes Public Offering Amid 52-Week Low

Mar 24 2026NASDAQ.COM

Outlook Therapeutics Initiates Public Offering of Common Stock

Mar 23 2026seekingalpha

Outlook Therapeutics Secures $18.4 Million Financing for LYTENAVA

Mar 17 2026NASDAQ.COM

Outlook Therapeutics Discusses FDA Response on ONS-5010 Approval Pathway

Mar 06 2026NASDAQ.COM

Outlook Therapeutics Provides FDA Meeting Update on ONS-5010

Mar 05 2026Newsfilter

OUTLOOK THERAPEUTICS INC - MEDICONSULT TO PROMOTE AND DISTRIBUTE LYTENAVA IN SWITZERLAND

Feb 19 2026moomoo

OUTLOOK THERAPEUTICS: COLLABORATION BOOSTS EUROPEAN GROWTH PLAN, LYTENAVA SET TO DEBUT IN SWITZERLAND IN 2027

Feb 19 2026moomoo

Outlook Therapeutics Requests FDA Meeting Following CRL for ONS-5010

Feb 11 2026Newsfilter

U.S. Stocks Close Higher on Friday, Nasdaq Slightly Declines, Market Sentiment Neutral

Jan 05 2026Benzinga

Health Care Stocks Mixed as NYSE Health Care Index Edges Up

Jan 02 2026Yahoo Finance

Intelligent Bio Solutions Plans $10 Million Private Placement, Shares Plunge 19.7%

Jan 02 2026Benzinga

ChowChow Cloud Reports 29% Revenue Growth in H1 2025

Jan 02 2026Benzinga

Baidu Inc. Proposes Spinoff of Kunlunxin, Shares Rise 11%

Jan 02 2026Benzinga